Sanofi at forefront of fight against COVID-19 in Q1 2020 (GlobeNewswire, Sanofi) - Apr 23, 2020 - "First-quarter 2020 Pharmaceutical sales were up 7.5% to €6,764 million, mainly driven by Dupixent...Dupixent® is also launched in adolescent atopic dermatitis in 12 countries, in asthma in 14 countries and in CRSwNP in 5 countries. Potentially as many as 68 additional country launches are planned across these indications in the remainder of 2020....Kevzara® (collaboration with Regeneron) sales were €55 million (up 80.0%) in the first quarter, of which €32 million was generated in the U.S. (up 72.2%) and €20 million in Europe (150.0%)....Anticipated regulatory submission of romilkimab for Systemic scleroderma in 2023 and beyond....Dupixent: Part A readout from pivotal trial in Eosinophilic Esophagitis in Q2-Q3 2020; Pivotal trial read-out in Asthma for 6-11 year old age group in Q4 2020....Anticipated regulatory submission for AD 6m - 5y old in 2022."
BLA • Clinical data • Regulatory • Sales • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation
|